Affinergy, a developer of site-specific biological delivery systems for drugs, has landed a deal with Boston Scientific to explore development of new coatings for cardiovascular stents.
Financial terms were not disclosed.
Affinergy is a spinout from Duke University.
Boston Scientific is a developer and manufacturer of medical devices.
“Boston Scientific has a long history as the innovation and marketshare leader in cardiovascular markets,” said Peyton Anderson, chief executive officer of Affinergy. “Our team is excited to work in a large medical device field where improving clinical outcomes can positively affect patients’ lives. Affinergy looks forward to building this relationship and moving our coatings into development as rapidly as possible.”
Affinergy: www.affinergy.com
